Aetion is a New York company generating real-world evidence for healthcare and life sciences with analytics software[1]. The company sells real-world evidence solutions to biopharmaceutical companies, medical device makers, payers and regulators through its Aetion Evidence Platform, which applies causal inference, epidemiologic methods and purpose-built AI to healthcare data[3]. Aetion's investors include Flare Capital Partners, NEA, Warburg Pincus, B Capital and leading life sciences and payer organizations[4]. In May 2025, Aetion launched Aetion Activate, a collaborative platform for biostatisticians and data scientists supporting both code and no-code users, and made the Aetion Evidence Platform available in AWS Marketplace[5]. Datavant completed its acquisition of Aetion on July 11, 2025, and Aetion became part of Datavant's Life Sciences business[2].
Funding history
- Datavant's May 15, 2025 acquisition announcement listed Aetion's investors as Flare Capital Partners, NEA, Warburg Pincus, B Capital and leading life sciences and payer organizations.[4]
Product
- Aetion sells real-world evidence solutions to biopharmaceutical companies, medical device makers, payers and regulators through its Aetion Evidence Platform, which applies causal inference, epidemiologic methods and purpose-built AI to healthcare data.[3]
- Alongside the May 15, 2025 Datavant deal announcement, Aetion launched Aetion Activate, a collaborative platform for biostatisticians and data scientists supporting both code and no-code users, and made the Aetion Evidence Platform available in AWS Marketplace.[5]
Status
- Datavant completed its acquisition of Aetion on July 11, 2025, and Aetion became part of Datavant's Life Sciences business.[2]
Backers
NEA
New Enterprise Associates, a venture capital firm investing in technology and healthcare from seed through IPO, with offices including Menlo Park.
Something wrong or missing? Send a correction. Fixed within 24 hours.